Flutamide (Eulexin)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Antiandrogen; non-steroidal. Inhibits androgen uptake and/or inhibits nuclear binding of androgen in target tissues.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1/27/1989: Initial FDA approval for use in combination with LHRH agonistic analogues (such as leuprolide acetate) for the treatment of metastatic prostatic carcinoma (stage D2). To achieve the benefit of the adjunctive therapy with EUFLEX, treatment must be started simultaneously using both drugs. EUFLEX Tablets are also indicated as an adjunctive therapy to orchiectomy, in order to achieve complete androgen blockade.
  • Also approved in combination with LHRH agonists are also indicated prior to and during definitive external beam radiotherapy for patients with bulky locally advanced Stage B2 and Stage C prostatic carcinoma.

Also known as

  • Brand names: Cytomid, Euflex, Eulexin, Flutamid, Flutatec, Lutamide, Proscan, Tamid

References